MAIA Biotechnology raises $1.0M via private placement of 494,096 shares at $2.034/sh and warrants

MAIA Biotechnology, Inc.

Gross proceeds $1.0M from sale of 494,096 shares at $2.034/sh and warrants to purchase same number at $2.26.
Director Stan Smith purchased 147,492 shares/warrants for ~$300k; Louie Ngar Yee purchased 19,665 for ~$40k.
Warrants exercisable at $2.26, commencing 6 months from issuance, term 5 years.
Net proceeds to fund first third of THIO-101 Part C trial for non-small cell lung cancer.
Closing expected on or about April 25, 2024.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

MAIA Biotechnology, Inc. entered into "Purchase Agreement" with certain accredited investors valued at aggregate purchase price of approximately $664,994 (effective 2024-04-22).

Action: entry
Agreement: equity purchase
Counterparty: certain accredited investors
Value: aggregate purchase price of approximately $664,994
Effective: 2024-04-22

Exact text from the filing

On April 22, 2024, MAIA Biotechnology, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Investors ”) for the issuance and sale in a private placement (the “ Private Placement ”) of: (i) 326,939 shares (the “ Investor Shares ”) of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), and (ii) warrants (the “ Investor Warrants ”) to purchase up to 326,939 shares of Common Stock, at a price per share of $2.034, for an aggregate purchase price of approximately $664,994.

View on SEC.gov

291 material agreements filed in the last 30 days. Browse all material agreements →

MAIA Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-106975

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.